Athira Pharma (NASDAQ:LONA) Price Target Lowered to $17.00 at Citizens Jmp

Athira Pharma (NASDAQ:LONA) had its target price reduced by stock analysts at Citizens Jmp from $18.00 to $17.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would suggest a potential upside of 113.03% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Piper Sandler began coverage on shares of Athira Pharma in a report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Wall Street Zen upgraded Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Athira Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Athira Pharma Trading Up 0.1%

NASDAQ:LONA opened at $7.98 on Monday. The firm has a market capitalization of $74.93 million, a price-to-earnings ratio of -1.53 and a beta of 2.05. Athira Pharma has a 1-year low of $3.52 and a 1-year high of $14.21. The business’s fifty day moving average price is $8.26 and its 200 day moving average price is $8.24.

Athira Pharma (NASDAQ:LONA) last issued its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Equities analysts forecast that Athira Pharma will post -3.12 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Focus Partners Wealth acquired a new stake in shares of Athira Pharma in the 3rd quarter valued at $35,000. Jane Street Group LLC bought a new position in Athira Pharma during the fourth quarter valued at about $100,000. Renaissance Technologies LLC lifted its position in shares of Athira Pharma by 44.7% in the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Athira Pharma during the 4th quarter worth about $969,000. Finally, Millennium Management LLC acquired a new position in shares of Athira Pharma during the 4th quarter valued at about $2,456,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.